ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Net Medical’s Adapts New FDA Rules on Test-To-Treat Service

ALBUQUERQUE, NM / ACCESSWIRE / July 12, 2022 / Net Medical (OTC PINK:NMXS) said today it has adapted new Federal Drug Administration (FDA) rules that provide free COVID treatments through pharmacy prescriptions in the company's Test-to-Treat program. The new rules provide greater access to timely treatments.

Following a Net Medical consultation, infected patients can now take the company's test report directly to a state-licensed pharmacist who can prescribe Paxlovid, Pfizer's COVID-19 antiviral treatment.

This comes after the U.S. Food and Drug Administration (FDA) revised its emergency use authorization of the drug last week for people who have been recently infected and are at high risk for severe disease.

Previously, only licensed doctors, nurses, and physician assistants were allowed to prescribe the treatment to patients. Experts say the adjustment recognizes the important role pharmacists have played and continue to play in the fight against COVID-19.

Net Medical CEO Dick Govatski said, "This change further expedites the treatment of those diagnosed by our Test-to-Treat program. We are continuing to work closely with the FDA for more effective solutions in dealing with COVID. Our daily tests are currently showing up to 20% of those tested on a daily basis are infected with COVID. While new strains of the disease appear to be less deadly than in the past, the prevalence of COVID in the general public is continuing."

Net Medical's Test-To-Treat program is particularly valuable for those living in rural areas in New Mexico and Arizona where testing services are limited.

Net Medical is among the few companies currently accepting insurance from all major carriers for telemedicine services. In addition, Net Medical is directly linked to the New Mexico Department of Health website.

For more information, call 505-255-1999 X 320. Visit www.netmedical.com. Email ir@netmedical.com

About Net Medical - publicly traded (OTC Pink:NMXS) since 1999.

Net Medical has two operating units. Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. The company's mobile fleet of vans provide COVID and flu testing in New Mexico for schools, companies, homeless shelters and nursing homes. The company provides a unique Test-To-Treat program for home and office care that combines both diagnostic and pharmaceutical services that are particularly valuable in rural communities. The lab also serves as a reference lab for physician offices and other facilities that lack services for complex virus diagnostics. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company maintains a 24/7/365 call center, software developers and telemedicine platforms.

Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.

SOURCE: Net Medical Xpress Solutions, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708226/Net-Medicals-Adapts-New-FDA-Rules-on-Test-To-Treat-Service

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.